Insider

Takeda Pharmaceutical Co. Ltd

TAK Health Care · 3 analyses · 3 expectations tracked

Insider tracks 3 open management expectations for this company. 2 insider sales recorded.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

Company history

October 2026

TAKEDA PHARMACEUTICAL CO LTD: 12 recorded developments from 2 official sources in 2026-10.

  • 2026-10-29: Amortization and impairment losses on intangible assets associated with products were 218.5 billion JPY in the six-month period ended September 30, 2026, down 35.1% at actual exchange rates. Source
  • 2026-10-29: Other operating expenses rose mainly because restructuring expenses increased by 52.4 billion JPY, reflecting the ongoing implementation of the transformation program. Source
  • 2026-10-29: Income tax expenses were 13.0 billion JPY, mainly due to deferred tax benefits from a reassessment of the recoverability of deferred tax assets. Source
  • 2026-10-29: In GI, sales in the United States were 351.8 billion JPY, up 10.3% at actual exchange rates, driven by favorable exchange rates against the U.S. dollar and growth of the subcutaneous formulation. Source
  • 2026-10-29: In GI, sales in Europe were 124.9 billion JPY, up 15.1% at actual exchange rates, due to favorable exchange rates against the euro and continued growth in patient numbers. Source
  • 2026-10-29: TRINTELLIX sales were 71.3 billion JPY, up 25.2% at actual exchange rates, mainly due to pricing favorability in the U.S., including a price increase and shifts in payer mix. Source
  • 2026-10-29: Net finance expenses rose to 88.0 billion JPY, mainly due to higher interest on the U.S. dollar senior guaranteed notes issued July 2, 2025, a building lease liability, and losses on investments in convertible notes. Source
  • 2026-10-29: Core operating profit in FY2026 H1 was 710.6 billion JPY, up 11.2% at actual exchange rates and 0.7% at constant exchange rates. Source
  • 2026-10-29: Revenue for the six months ended September 30, 2026 was 2,406,997 million JPY, up 8.4% from the same period a year earlier. Source
  • 2026-10-29: Net profit attributable to owners of the Company for the six months ended September 30, 2026 was 305,626 million JPY, up 171.8%. Source
  • 2026-10-29: Forecast revenue for the fiscal year ending March 31, 2027 is 4,700,000 million JPY, up 4.3% from the previous fiscal year. Source
  • 2026-10-29: Management guidance for the fiscal year ending March 31, 2027 on a constant exchange rate basis: core revenue growth low-single digit % decline, core operating profit mid-single digit % decline, core EPS low-teens % decline. Source

September 2026

TAKEDA PHARMACEUTICAL CO LTD: 12 recorded developments from 1 official source in 2026-09.

  • 2026-09-14: FDA accepted Takeda's New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Source
  • 2026-09-14: Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. Source
  • 2026-09-14: Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. Source
  • 2026-09-14: In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Source
  • 2026-09-14: This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or ot Source
  • 2026-09-14: The European Medicines Agency (EMA) also accepted Takeda's new marketing authorization application (MAA) for zasocitinib, initiating the review process for the treatment of moderate-to-severe plaque psoriasis. Source
  • 2026-09-14: Takeda plans to submit additional applications for plaque psoriasis with global regulatory authorities to bring zasocitinib to people living with psoriasis worldwide. Source
  • 2026-09-14: Zasocitinib is an investigational, next-generation, highly selective and potent oral TYK2 inhibitor that maintains 24-hour inhibition of IL-23 plus other core disease-driving immune pathways. It has the potential to be a leading oral treatment option for people living with psoriasis that Source
  • 2026-09-14: Zasocitinib has more than 1-million-fold greater selectivity for TYK2 compared to other JAK enzymes, which could maximize TYK2 inhibition without impacting JAK1, 2 and 3 signaling, based on in vitro data. Source
  • 2026-09-14: Takeda is currently evaluating the safety and efficacy of zasocitinib in Phase 3 studies in psoriatic arthritis and Phase 2 studies in Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa. Source
  • 2026-09-14: The co-primary endpoints were the proportion of zasocitinib-treated patients achieving sPGA 0/1 and PASI 75 response compared to placebo at week 16. Ranked secondary endpoints included comparisons versus placebo (week 16) and apremilast (week 16 and week 24). Source
  • 2026-09-14: We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Takeda Pharmaceutical Co. Ltd TAK———
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Expectations and reality

Open

  • Forecast core revenue for the fiscal year ending March 31, 2027 is 4,700,000 million JPY, and core operating profit is 1,190,000 million JPY.

    Said October 29, 2026 · Period named: For the Fiscal Year Ending March 31, 2027 · Source · Our article

    AI assessment, provisional no new evidence in later reports yet (as of November 12, 2026) · Later article

  • The NDA filing has no significant impact on the full year consolidated financial forecast for the fiscal year ending March 31, 2027.

    Said September 14, 2026 · Period named: fiscal year ending March 31, 2027 · Source · Our article

    AI assessment, provisional no new evidence in later reports yet (as of November 12, 2026) · Later article

  • Zasocitinib is currently under FDA Priority Review, with a decision anticipated in the first quarter of 2027. If approved, zasocitinib could become available to appropriate patients after FDA approval.

    Said September 14, 2026 · Period named: first quarter of 2027 · Source · Our article

    AI assessment, provisional no new evidence in later reports yet (as of November 12, 2026) · Later article

What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
November 4, 2026Giles Richard PlatfordSale notice filed55,617$20.90$1,162,395SEC
November 2, 2026Teresa Marie BitettiSale46,609$20.89$973,662SEC
November 1, 2026Teresa BitettiPlanned sale46,609—$940,104SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
Capital Research Global Investors26,952,673$490,269,122+39.7%Q3 2026
Fidelity (FMR)10,974,215$199,620,966+14.3%Q3 2026
BlackRock3,938,925$71,649,050+6.8%Q3 2026
D. E. Shaw & Co.3,140,091$57,118,255+53.2%Q3 2026
Renaissance Technologies2,292,700$41,704,213-10.7%Q3 2026
Two Sigma Investments1,595,296$29,018,434+228.4%Q3 2026
Millennium Management1,333,076$24,248,652+26.9%Q3 2026
Citadel Advisors798,062$14,516,748+374.7%Q3 2026
Bridgewater Associates21,276$387,010—Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.